Biotechnology Updated results from the ASCEND Phase III trial showed that Calquence (acalabrutinib) maintained a statistically-significant progression-free survival (PFS) benefit at three years compared to investigator’s choice of rituximab combined with either idelalisib (IdR) or bendamustine (BR) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, said the drug’s developer, Anglo-Swedish pharma major AstraZeneca 13 December 2021